Can we predict relapse in Graves' disease? Results from a systematic review and meta-analysis

European Journal of Endocrinology

Volumn 176, Issue 1, 2017, Pages 87-97

  Struja, Tristan ^a   Fehlberg, Hannah ^a   Kutz, Alexander ^a   Guebelin, Larissa ^a   Degen, Christian ^a   Mueller, Beat ^a,b   Schuetz, Philipp ^a,b  

^a CANTONAL HOSPITAL AARAU   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

THYROXINE;

ARTICLE; CASE CONTROL STUDY; COCHRANE LIBRARY; ECHOGRAPHY; EMBASE; FOLLOW UP; FREE THYROXINE INDEX; GOITER; GRAVES DISEASE; HUMAN; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MEDLINE; ORGAN SIZE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RISK ASSESSMENT; SEX RATIO; SMOKING; SYSTEMATIC REVIEW; THYROID VOLUME; FEMALE; MALE; META ANALYSIS; PATHOLOGY; RECURRENT DISEASE; RISK FACTOR;

FEMALE; GRAVES DISEASE; HUMANS; MALE; RECURRENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 85002496941     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-16-0725     Document Type: Article

References (74)

1. Genovese BM, Noureldine SI, Gleeson EM, Tufano RP & Kandil E. What is the best definitive treatment for Graves' disease? A systematic review of the existing literature. Annals of Surgical Oncology 2013 20 660-667. (doi:10.1245/s10434-012-2606-x)
2. Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A & Fallahi P. Autoimmune thyroid disorders. Autoimmunity Reviews 2015 14 174-180. (doi:10.1016/j.autrev.2014.10.016)
3. Orgiazzi J. Thyroid autoimmunity. Presse Médicale 2012 41 25. (doi:10.1016/j.lpm.2012.10.002)
4. Franklyn JA & Boelaert K. Thyrotoxicosis. Lancet 2012 379 1155-1166. (doi:10.1016/S0140-6736(11)60782-4)
5. Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH & Bahn RS. Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis. Journal of Clinical Endocrinology and Metabolism 2013 98 3671-3677. (doi:10.1210/jc.2013-1954)
6. Abraham P, Avenell A, McGeoch SC, Clark LF & Bevan JS. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database of Systematic Reviews 2010 CD003420. (doi:10.1002/14651858.CD003420.pub4)
7. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J & Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009 6 e1000100. (doi:10.1371/journal.pmed.1000100)
8. Higgins JPT & Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0, updated 2011. (available at: http://handbook.cochrane.org/). Accessed on 16 October 2015.
9. Wang PW, Liu RT, Juo SHH, Wang ST, Hu YH, Hsieh CJ, Chen MH, Chen IY & Wu CL. Cytotoxic T lymphocyte-associated molecule-4 polymorphism and relapse of Graves' hyperthyroidism after antithyroid withdrawal. Journal of Clinical Endocrinology and Metabolism 2004 89 169-173. (doi:10.1210/jc.2003-030854)
10. Orunesu E, Bagnasco M, Salmaso C, Altrinetti V, Bernasconi D, Del Monte P, Pesce G, Marugo M & Mela GS. Use of an artificial neural network to predict Graves' disease outcome within 2 years of drug withdrawal. European Journal of Clinical Investigation 2004 34 210-217. (doi:10.1111/j.1365-2362.2004.01318.x)
11. Sonnet E, Massart C, Gibassier J, Allannic H & Maugendre D. Longitudinal study of soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves' disease. Journal of Endocrinological Investigation 1999 22 430-435. (doi:10.1007/bf03343586)
12. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E & Pinchera A. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997 7 369-375. (doi:10.1089/thy.1997.7.369)
13. Massart C, Guilhem I, Gibassier J, Allannic H & Nicol M. Comparison of thyroperoxidase and microsomal antibody assays in sera from patients with Graves disease. Clinical Chemistry 1991 37 1777-1780.
14. de Bruin TW, Bolk JH, Bussemaker JK, Stijnen T, Schreuder GM, de Vries RR & van der Heide D. Graves' disease: immunological and immunogenetic indicators of relapse. British Medical Journal (Clinical Research Edition) 1988 296 1292-1295. (doi:10.1136/bmj.296.6632.1292)
15. Kimball LE, Kulinskaya E, Brown B, Johnston C & Farid NR. Does smoking increase relapse rates in Graves' disease? Journal of Endocrinological Investigation 2002 25 152-157. (doi:10.1007/bf03343979)
16. Laurberg P, Buchholtz Hansen PE & Iversen E. Goitre size and outcome of medical treatment of Graves' disease. Acta Endocrinologica 1986 111 39-43. (doi:10.1530/acta.0.1110039)
17. Takaichi Y, Tamai H, Honda K, Nagai K, Kuma K & Nakagawa T. The significance of antithyroglobulin and antithyroidal microsomal antibodies in patients with hyperthyroidism due to Graves' disease treated with antithyroidal drugs. Journal of Clinical Endocrinology and Metabolism 1989 68 1097-1100. (doi:10.1210/jcem-68-6-1097)
18. Yamada T, Aizawa T, Koizumi Y, Komiya I, Ichikawa K & Hashizume K. Age-related therapeutic response to antithyroid drug in patients with hyperthyroid Graves' disease. Journal of the American Geriatrics Society 1994 42 513-516. (doi:10.1111/j.1532-5415.1994.tb04973.x)
19. Khanna CM, Shankar LR, Jaggi CB, Bansal JK & Chugh P. Predictor of outcome of hyperthyroidism due to Graves disease: serum triiodothyronine/thyroxine ratio. Journal of the Association of Physicians of India 1996 44 98-101.
20. Wilson R, McKillop JH & Henderson N. The ability of the serum thyrotrophin receptor antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves's disease. Clinical Endocrinology 1986 25 151-156. (doi:10.1111/j.1365-2265.1986.tb01676.x)
21. Scottish Intercollegiate Guidelines Network (SIGN), 2015. (available at: http://www.sign.ac.uk/index.html). Accessed on 16 October 2015.
22. Leon-Guerrero A & Frankfort-Nachmias C. Essentials of Social Statistics for a Diverse Society. Thousand Oaks, CA, USA: SAGE, 2012.
23. DerSimonian R & Laird N. Meta-analysis in clinical trials revisited. Contemporary Clinical Trials 2015 45 (Part A) 139-145. (doi:10.1016/j.cct.2015.09.002)
24. Borenstein M, Hedges LV, Higgins JPT & Rothstein HR. Introduction to Meta-Analysis. Chichester, UK: Wiley, 2010.
25. Higgins JPT, Thompson SG, Deeks JJ & Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003 327 557-560. (doi:10.1136/bmj.327.7414.557)
26. Raghunathan TE, Lepkowski JM, van Hoewyk J & Solenberger P. A multivariate technique for multiply imputing missing values using a sequence of regression models. Survey Methodology 2001 27 85-96.
27. Thompson SG & Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Statistics in Medicine 2002 21 1559-1573. (doi:10.1002/sim.1187)
28. Egger M, Davey Smith G, Schneider M & Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997 315 629-634. (doi:10.1136/bmj.315.7109.629)
29. Yamada T, Komiya I, Miyahara Y, Komatsu M, Shima I, Inazawa T & Aizawa T. Effect of methimazole treatment for 2 years on circulating IL-4, IgE, TBII, and TSAb in patients with hyperthyroid Graves' disease. Endocrine Journal 2006 53 783-788. (doi:10.1507/endocrj.K06-054)
30. Wilson R, McKillop JH & Pearson DWM. Relapse of Graves' disease after medical therapy: predictive value of thyroidal technetium-99m uptake and serum thyroid stimulating hormone receptor antibody levels. Journal of Nuclear Medicine 1985 26 1024-1028.
31. Wang PW, Liu RT, Tung SC, Chien WY, Lu YC, Chen CH, Kuo MC, Hsieh JR & Wang ST. Outcome of Graves' disease after antithyroid drug treatment in Taiwan. Journal of the Formosan Medical Association 1998 97 619-625.
32. Wang PW, Chen IY, Juo SH, Hsi E, Liu RT & Hsieh CJ. Genotype and phenotype predictors of relapse of graves' disease after antithyroid drug withdrawal. European Thyroid Journal 2013 1 251-258. (doi:10.1159/000342621)
33. Vitti P, Rago T, Mancusi F, Pallini S, Tonacchera M, Santini F, Chiovato L, Marcocci C & Pinchera A. Thyroid hypoechogenic pattern at ultrasonography as a tool for predicting recurrence of hyperthyroidism after medical treatment in patients with Graves' disease. Acta Endocrinologica 1992 126 128-131.
34. van Ouwerkerk BM, Krenning EP & Docter R. Cellular and humoral immunity in patients with hyperthyroid Graves' disease before, during and after antithyroid drug treatment. Clinical Endocrinology 1987 26 385-394. (doi:10.1111/j.1365-2265.1987.tb00795.x)
35. Tanrikulu S, Erbil Y, Ademoglu E, Issever H, Barbaros U, Kutluturk F, Ozarmagan S & Tezelman S. The predictive value of CTLA-4 and Tg polymorphisms in the recurrence of Graves' disease after antithyroid withdrawal. Endocrine 2006 30 377-381. (doi:10.1007/s12020-006-0017-0)
36. Takamatsu J, Kuma K & Mozai T. Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves' disease. Journal of Clinical Endocrinology and Metabolism 1986 62 980-983. (doi:10.1210/jcem-62-5-980)
37. Stefanic M & Karner I. Thyroid peroxidase autoantibodies are associated with a lesser likelihood of late reversion to hyperthyroidism after successful non-ablative treatment of Graves' disease in Croatian patients. Journal of Endocrinological Investigation 2014 37 71-77. (doi:10.1007/s40618-013-0026-9)
38. Soveid M, Shaabani A, Ghaedi Gh H, Jafari SM & Omrani G. Prognostic factors in the relapse of Graves' disease following treatment with antithyroid drugs. Iranian Journal of Medical Sciences 2003 28 106-110.
39. Shahbazian H, Saiedinia S & Aleali AM. Outcome of graves disease after anti-thyroid drug treatment in south west of Iran. Pakistan Journal of Medical Sciences 2012 28 445-449.
40. Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, Hensen J, Finke R, Bogner U, Mayr WR et al. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinologica 1989 120 689-701. (doi:10.1530/acta.0.1200689)
41. Schleusener H, Schwander J, Holl G, Badenhoop K, Hensen J, Finke R, Schernthaner G, Mayr WR & Kotulla P. Do HLA-DR-typing and measurement of TSH-receptor antibodies help in the prediction of the clinical course of Graves' thyrotoxicosis after antithyroid drug treatment? Acta Endocrinologica: Supplementum 1987 281 318-324.
42. Schifferdecker E, Kuhnl P, Schoffling K, Manfras B, Holzberger G, Spielmann W & Bohm BO. Immunogenetic markers in patients with Graves' disease. Klinische Wochenschrift 1991 69 256-260. (doi:10.1007/BF01666851)
43. Scazziga BR. Drug therapy of Basedow's disease. Long term functional results (302 cases). Schweizerische Medizinische Wochenschrift 1977 107 423-427.
44. Romaldini JH, Bromberg N, Werner RS, Tanaka LM, Rodrigues HF, Werner MC, Farah CS & Reis LC. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 1983 57 563-570. (doi:10.1210/jcem-57-3-563)
45. Prakash R. Prediction of remission in Graves' disease treated with long-term carbimazole therapy: evaluation of technetium-99m thyroid uptake and TSH concentrations as prognostic indicators. European Journal of Nuclear Medicine 1996 23 118-122. (doi:10.1007/BF01731833)
46. Park SM, Cho YY, Joung JY, Sohn SY, Kim SW & Chung JH. Excessive iodine intake does not increase the recurrence rate of Graves' disease after withdrawal of the antithyroid drug in an iodine-replete area. European Thyroid Journal 2015 4 36-42. (doi:10.1159/000375261)
47. Orhan Y, Azezli A, Aral F, Tascioglu C, Molvalilar S & Sencer E. The frequency of remission and relapse in Graves' disease was investigated. Istanbul Üniversitesi Tip Fakültesi Mecmuasi 1992 55 525-530.
48. Murakami M, Koizumi Y, Aizawa T, Yamada T, Takahashi Y, Watanabe T & Kamoi K. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission. Journal of Clinical Endocrinology and Metabolism 1988 66 103-108. (doi:10.1210/jcem-66-1-103)
49. Lucas A, Salinas I, Rius F, Pizarro E, Granada ML, Foz M & Sanmarti A. Medical therapy of Graves' disease: does thyroxine prevent recurrence of hyperthyroidism? Journal of Clinical Endocrinology and Metabolism 1997 82 2410-2413. (doi:10.1210/jcem.82.8.4118)
50. Komiya I, Yamada T, Sato A, Kouki T, Nishimori T & Takasu N. Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and interleukin 13. Journal of Clinical Endocrinology and Metabolism 2001 86 3540-3544. (doi:10.1210/jcem.86.8.7734)
51. Kim KW, Park YJ, Kim TY, Park DJ, Park KS & Cho BY. Susceptible alleles of the CD40 and CTLA-4 genes are not associated with the relapse after antithyroid withdrawal in Graves' disease. Thyroid 2007 17 1229-1234. (doi:10.1089/thy.2007.0011)
52. Kim TY, Park YJ, Park DJ, Chung H-K, Kim WB, Kohn LD & Cho BY. Epitope heterogeneity of thyroid-stimulating antibodies predicts long-term outcome in Graves' patients treated with antithyroid drugs. Journal of Clinical Endocrinology and Metabolism 2003 88 117-124. (doi:10.1210/jc.2002-020389)
53. Jonas M, Ambroziak U, Bednarczuk T & Nauman J. Predicting a relapse of Graves' hyperthyroidism in adults during the early phase of treatment with anti-thyroid drugs. Endokrynologia Polska 2006 57 596-604.
54. Irvine WJ, Gray RS, Morris PJ & Ting A. Correlation of HLA and thyroid antibodies with clinical course of thyrotoxicosis treated with antithyroid drugs. Lancet 1977 2 898-900. (doi:10.1016/S0140-6736(77)90833-9)
55. Hou X, Li Y, Li J, Wang W, Fan C, Wang H, Zhang H, Shan Z & Teng W. Development of thyroid dysfunction and autoantibodies in Graves' multiplex families: an eight-year follow-up study in Chinese Han pedigrees. Thyroid 2011 21 1353-1358. (doi:10.1089/thy.2011.0035)
56. Hoermann R, Quadbeck B, Roggenbuck U, Szabolcs I, Pfeilschifter J, Meng W, Reschke K, Hackenberg K, Dettmann J, Prehn B et al. Relapse of Graves' disease after successful outcome of antithyroid drug therapy: Results of a prospective randomized study on the use of levothyroxine. Thyroid 2002 12 1119-1128. (doi:10.1089/105072502321085225)
57. Hayashi M, Kouki T, Takasu N, Sunagawa S & Komiya I. Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients. European Journal of Endocrinology 2008 158 817-822. (doi:10.1530/EJE-07-0649)
58. Hansen PEB. The recurrence-rate following thyrostatic treatment of patients with hyperthyroidism and diffuse goitre (Graves' disease). The relationship to the concentrations of inorganic iodine in the plasma. Ugeskrift for Laeger 1983 145 980-982.
59. Guilhem I, Massart C, Poirier JY & Maugendre D. Differential evolution of thyroid peroxidase and thyrotropin receptor antibodies in Graves' disease: thyroid peroxidase antibody activity reverts to pretreatment level after carbimazole withdrawal. Thyroid 2006 16 1041-1045. (doi:10.1089/thy.2006.16.1041)
60. Glowacka D, Loesch C, Johnson KT, Mann K, Esser J, Morgenthaler NG, Siffert W, Schmid KW & Eckstein AK. The T393C polymorphism of the Galphas gene (GNAS1) is associated with the course of Graves' disease. Hormone and Metabolic Research 2009 41 430-435. (doi:10.1055/s-0029-1220902)
61. Glinoer D, Nayer P de & Bex M. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. European Journal of Endocrinology/European Federation of Endocrine Societies 2001 144 475-483. (doi:10.1530/eje.0.1440475)
62. Edmonds CJ & Tellez M. Treatment of Graves' disease by carbimazole: high dose with thyroxine compared to titration dose. European Journal of Endocrinology/European Federation of Endocrine Societies 1994 131 120-124. (doi:10.1530/eje.0.1310120)
63. Eckstein AK, Lax H, Losch C, Glowacka D, Plicht M, Mann K, Esser J & Morgenthaler NG. Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clinical Endocrinology 2007 67 607-612. (doi:10.1111/j.1365-2265.2007.02933.x)
64. Duprey J & Colliard M. Results of treatment of Graves' disease by antithyroid drugs. Report of 90 cases (author's transl). Annales d'endocrinologie 1981 42 233-249.
65. Dauksiene D, Dauksa A & Mickuviene N. Independent pretreatment predictors of Graves' disease outcome. Medicina 2013 49 427-434.
66. Corrales JJ, Lopez A, Ciudad J & Orfao A. The distribution of the major peripheral blood T, B and NK cell subsets does not predict the clinical outcome of Graves' disease patients after methimazole therapy. Journal of Biological Regulators and Homeostatic Agents 2001 14 193-199.
67. Choo YK, Yoo WS, Kim DW & Chung HK. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease. Thyroid 2010 20 949-954. (doi:10.1089/thy.2009.0126)
68. Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, Pirola I, Martino E de & Rosei EA. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study. Endocrine Journal 2007 54 713-720. (doi:10.1507/endocrj.K06-069)
69. Bo Youn C, Min Ho S, Ka Hee Y, Hong Kyo L, Chang-Soon K & Hun Ki M. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease. Clinical Endocrinology 1992 36 585-590. (doi:10.1111/j.1365-2265.1992.tb02269.x)
70. Allannic H, Fauchet R & Lorcy Y. A prospective study of the relationship between relapse of hyperthyroid Graves' disease after antithyroid drugs and HLA haplotype. Journal of Clinical Endocrinology and Metabolism 1983 57 719-722. (doi:10.1210/jcem-57-4-719)
71. Winsa B, Adami HO, Bergstrom R, Gamstedt A, Dahlberg PA, Adamson U, Jansson R & Karlsson A. Stressful life events and Graves' disease. Lancet 1991 338 1475-1479. (doi:10.1016/0140-6736(91)92298-G)
72. Struja TM, Guebelin L, Kutz A, Fehlberg H, Mueller B & Schuetz P. Does immunosuppressive therapy improve outcomes in Graves' disease? A systematic review and meta-analysis. Thyroid 2016 26 634-640. (doi:10.1089/thy.2015.0647)
73. Nygaard B. Hyperthyroidism (primary). BMJ Clinical Evidence 2010 2010 0605.
74. Vos XG, Endert E, Zwinderman AH, Tijssen JGP & Wiersinga WM. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves' hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 2016 101 1381-1389. (doi:10.1210/jc.2015-3644)